Treatment of corneal transplant rejection in humans with anti-interferon-γ antibodies
PURPOSE: To determine efficacy of anti-human interferon-γ F(ab′)2 (Fabs) in treating corneal transplant rejection after penetrating keratoplasty. DESIGN: Interventional case series. METHODS: Anti-interferon-γ Fabs derived from goat antihuman interferon-γ antibodies were used for instillations in 13...
Gespeichert in:
| Veröffentlicht in: | American journal of ophthalmology 2002-06, Vol.133 (6), p.829-830 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 830 |
|---|---|
| container_issue | 6 |
| container_start_page | 829 |
| container_title | American journal of ophthalmology |
| container_volume | 133 |
| creator | Skurkovich, Simon Kasparov, Alexander Narbut, Nikolai Skurkovich, Boris |
| description | PURPOSE: To determine efficacy of anti-human interferon-γ F(ab′)2 (Fabs) in treating corneal transplant rejection after penetrating keratoplasty.
DESIGN: Interventional case series.
METHODS: Anti-interferon-γ Fabs derived from goat antihuman interferon-γ antibodies were used for instillations in 13 patients (13 eyes) who experienced corneal transplant rejection after penetrating keratoplasty. Fabs were administered in one or three treatment course(s) as eyedrops given three times daily for 7 to 10 days.
RESULTS: In 10 patients, 2 to 3 days after start of one treatment course, transplant transparency improved, and edema decreased. At the end of week 1, the transplant became almost fully transparent, and eye inflammation disappeared. Visual acuity increased from 0.2 to 0.3. In the other three patients, three treatment courses were needed for comparable improvement. Improvement was maintained through follow-up—an average of 7 months.
CONCLUSION: Antihuman interferon-γ Fabs may be safe and effective in halting corneal transplant rejection after penetrating keratoplasty. |
| doi_str_mv | 10.1016/S0002-9394(02)01433-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71726941</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002939402014332</els_id><sourcerecordid>71726941</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-a5982d0ffb3b4a26ed10319279c17dc3d0c3dfae49ca71475faf9ca09facbfe73</originalsourceid><addsrcrecordid>eNqFkM1OAyEQgInR2Fp9BM2ejB5W-dku5WRM419i4sHqlbDskNLsLhVYjc_le_hM0p_o0QMZmPmGgQ-hY4IvCCbl5TPGmOaCieIM03NMCsZyuoOGZMJFTiaC7KLhLzJAByEs0rHkBd9HA0IxK0suhuh15kHFFrqYOZNp5ztQTRa96sKyUSnrYQE6WtdltsvmfZsK2YeN8ywVbW67CN6Ad13-_bVOVa62EA7RnlFNgKNtHKGX25vZ9D5_fLp7mF4_5pqVJOZqLCa0xsZUrCoULaEmmBFBudCE15rVOC2joBBacVLwsVEmbbEwSlcGOBuh0829S-_eeghRtjZoaNLTwfVBcsJpKQqSwPEG1N6F4MHIpbet8p-SYLkSKtdC5cqWTHEtVNLUd7Id0Fct1H9dW4MJuNoAkL75bsHLoC10GmrrkzhZO_vPiB8WbIgv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71726941</pqid></control><display><type>article</type><title>Treatment of corneal transplant rejection in humans with anti-interferon-γ antibodies</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Skurkovich, Simon ; Kasparov, Alexander ; Narbut, Nikolai ; Skurkovich, Boris</creator><creatorcontrib>Skurkovich, Simon ; Kasparov, Alexander ; Narbut, Nikolai ; Skurkovich, Boris</creatorcontrib><description>PURPOSE: To determine efficacy of anti-human interferon-γ F(ab′)2 (Fabs) in treating corneal transplant rejection after penetrating keratoplasty.
DESIGN: Interventional case series.
METHODS: Anti-interferon-γ Fabs derived from goat antihuman interferon-γ antibodies were used for instillations in 13 patients (13 eyes) who experienced corneal transplant rejection after penetrating keratoplasty. Fabs were administered in one or three treatment course(s) as eyedrops given three times daily for 7 to 10 days.
RESULTS: In 10 patients, 2 to 3 days after start of one treatment course, transplant transparency improved, and edema decreased. At the end of week 1, the transplant became almost fully transparent, and eye inflammation disappeared. Visual acuity increased from 0.2 to 0.3. In the other three patients, three treatment courses were needed for comparable improvement. Improvement was maintained through follow-up—an average of 7 months.
CONCLUSION: Antihuman interferon-γ Fabs may be safe and effective in halting corneal transplant rejection after penetrating keratoplasty.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/S0002-9394(02)01433-2</identifier><identifier>PMID: 12036679</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Antibodies - therapeutic use ; Cornea - drug effects ; Cornea - physiopathology ; Goats ; Graft Rejection - drug therapy ; Graft Rejection - etiology ; Graft Rejection - physiopathology ; Graft Survival - drug effects ; Humans ; Immunoglobulin Fab Fragments - therapeutic use ; Interferon-gamma - immunology ; Keratoplasty, Penetrating - adverse effects ; Male ; Middle Aged ; Ophthalmic Solutions ; Recombinant Proteins ; Safety ; Treatment Outcome ; Visual Acuity</subject><ispartof>American journal of ophthalmology, 2002-06, Vol.133 (6), p.829-830</ispartof><rights>2002 Elsevier Science Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-a5982d0ffb3b4a26ed10319279c17dc3d0c3dfae49ca71475faf9ca09facbfe73</citedby><cites>FETCH-LOGICAL-c361t-a5982d0ffb3b4a26ed10319279c17dc3d0c3dfae49ca71475faf9ca09facbfe73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-9394(02)01433-2$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12036679$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Skurkovich, Simon</creatorcontrib><creatorcontrib>Kasparov, Alexander</creatorcontrib><creatorcontrib>Narbut, Nikolai</creatorcontrib><creatorcontrib>Skurkovich, Boris</creatorcontrib><title>Treatment of corneal transplant rejection in humans with anti-interferon-γ antibodies</title><title>American journal of ophthalmology</title><addtitle>Am J Ophthalmol</addtitle><description>PURPOSE: To determine efficacy of anti-human interferon-γ F(ab′)2 (Fabs) in treating corneal transplant rejection after penetrating keratoplasty.
DESIGN: Interventional case series.
METHODS: Anti-interferon-γ Fabs derived from goat antihuman interferon-γ antibodies were used for instillations in 13 patients (13 eyes) who experienced corneal transplant rejection after penetrating keratoplasty. Fabs were administered in one or three treatment course(s) as eyedrops given three times daily for 7 to 10 days.
RESULTS: In 10 patients, 2 to 3 days after start of one treatment course, transplant transparency improved, and edema decreased. At the end of week 1, the transplant became almost fully transparent, and eye inflammation disappeared. Visual acuity increased from 0.2 to 0.3. In the other three patients, three treatment courses were needed for comparable improvement. Improvement was maintained through follow-up—an average of 7 months.
CONCLUSION: Antihuman interferon-γ Fabs may be safe and effective in halting corneal transplant rejection after penetrating keratoplasty.</description><subject>Animals</subject><subject>Antibodies - therapeutic use</subject><subject>Cornea - drug effects</subject><subject>Cornea - physiopathology</subject><subject>Goats</subject><subject>Graft Rejection - drug therapy</subject><subject>Graft Rejection - etiology</subject><subject>Graft Rejection - physiopathology</subject><subject>Graft Survival - drug effects</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - therapeutic use</subject><subject>Interferon-gamma - immunology</subject><subject>Keratoplasty, Penetrating - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ophthalmic Solutions</subject><subject>Recombinant Proteins</subject><subject>Safety</subject><subject>Treatment Outcome</subject><subject>Visual Acuity</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1OAyEQgInR2Fp9BM2ejB5W-dku5WRM419i4sHqlbDskNLsLhVYjc_le_hM0p_o0QMZmPmGgQ-hY4IvCCbl5TPGmOaCieIM03NMCsZyuoOGZMJFTiaC7KLhLzJAByEs0rHkBd9HA0IxK0suhuh15kHFFrqYOZNp5ztQTRa96sKyUSnrYQE6WtdltsvmfZsK2YeN8ywVbW67CN6Ad13-_bVOVa62EA7RnlFNgKNtHKGX25vZ9D5_fLp7mF4_5pqVJOZqLCa0xsZUrCoULaEmmBFBudCE15rVOC2joBBacVLwsVEmbbEwSlcGOBuh0829S-_eeghRtjZoaNLTwfVBcsJpKQqSwPEG1N6F4MHIpbet8p-SYLkSKtdC5cqWTHEtVNLUd7Id0Fct1H9dW4MJuNoAkL75bsHLoC10GmrrkzhZO_vPiB8WbIgv</recordid><startdate>20020601</startdate><enddate>20020601</enddate><creator>Skurkovich, Simon</creator><creator>Kasparov, Alexander</creator><creator>Narbut, Nikolai</creator><creator>Skurkovich, Boris</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020601</creationdate><title>Treatment of corneal transplant rejection in humans with anti-interferon-γ antibodies</title><author>Skurkovich, Simon ; Kasparov, Alexander ; Narbut, Nikolai ; Skurkovich, Boris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-a5982d0ffb3b4a26ed10319279c17dc3d0c3dfae49ca71475faf9ca09facbfe73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Animals</topic><topic>Antibodies - therapeutic use</topic><topic>Cornea - drug effects</topic><topic>Cornea - physiopathology</topic><topic>Goats</topic><topic>Graft Rejection - drug therapy</topic><topic>Graft Rejection - etiology</topic><topic>Graft Rejection - physiopathology</topic><topic>Graft Survival - drug effects</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - therapeutic use</topic><topic>Interferon-gamma - immunology</topic><topic>Keratoplasty, Penetrating - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ophthalmic Solutions</topic><topic>Recombinant Proteins</topic><topic>Safety</topic><topic>Treatment Outcome</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Skurkovich, Simon</creatorcontrib><creatorcontrib>Kasparov, Alexander</creatorcontrib><creatorcontrib>Narbut, Nikolai</creatorcontrib><creatorcontrib>Skurkovich, Boris</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Skurkovich, Simon</au><au>Kasparov, Alexander</au><au>Narbut, Nikolai</au><au>Skurkovich, Boris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of corneal transplant rejection in humans with anti-interferon-γ antibodies</atitle><jtitle>American journal of ophthalmology</jtitle><addtitle>Am J Ophthalmol</addtitle><date>2002-06-01</date><risdate>2002</risdate><volume>133</volume><issue>6</issue><spage>829</spage><epage>830</epage><pages>829-830</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><abstract>PURPOSE: To determine efficacy of anti-human interferon-γ F(ab′)2 (Fabs) in treating corneal transplant rejection after penetrating keratoplasty.
DESIGN: Interventional case series.
METHODS: Anti-interferon-γ Fabs derived from goat antihuman interferon-γ antibodies were used for instillations in 13 patients (13 eyes) who experienced corneal transplant rejection after penetrating keratoplasty. Fabs were administered in one or three treatment course(s) as eyedrops given three times daily for 7 to 10 days.
RESULTS: In 10 patients, 2 to 3 days after start of one treatment course, transplant transparency improved, and edema decreased. At the end of week 1, the transplant became almost fully transparent, and eye inflammation disappeared. Visual acuity increased from 0.2 to 0.3. In the other three patients, three treatment courses were needed for comparable improvement. Improvement was maintained through follow-up—an average of 7 months.
CONCLUSION: Antihuman interferon-γ Fabs may be safe and effective in halting corneal transplant rejection after penetrating keratoplasty.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>12036679</pmid><doi>10.1016/S0002-9394(02)01433-2</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9394 |
| ispartof | American journal of ophthalmology, 2002-06, Vol.133 (6), p.829-830 |
| issn | 0002-9394 1879-1891 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71726941 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Antibodies - therapeutic use Cornea - drug effects Cornea - physiopathology Goats Graft Rejection - drug therapy Graft Rejection - etiology Graft Rejection - physiopathology Graft Survival - drug effects Humans Immunoglobulin Fab Fragments - therapeutic use Interferon-gamma - immunology Keratoplasty, Penetrating - adverse effects Male Middle Aged Ophthalmic Solutions Recombinant Proteins Safety Treatment Outcome Visual Acuity |
| title | Treatment of corneal transplant rejection in humans with anti-interferon-γ antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T20%3A38%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20corneal%20transplant%20rejection%20in%20humans%20with%20anti-interferon-%CE%B3%20antibodies&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Skurkovich,%20Simon&rft.date=2002-06-01&rft.volume=133&rft.issue=6&rft.spage=829&rft.epage=830&rft.pages=829-830&rft.issn=0002-9394&rft.eissn=1879-1891&rft_id=info:doi/10.1016/S0002-9394(02)01433-2&rft_dat=%3Cproquest_cross%3E71726941%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71726941&rft_id=info:pmid/12036679&rft_els_id=S0002939402014332&rfr_iscdi=true |